Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
138.21
+2.13 (1.57%)
At close: Jun 10, 2025, 4:00 PM
138.99
+0.78 (0.56%)
After-hours: Jun 10, 2025, 6:34 PM EDT
Krystal Biotech Revenue
Krystal Biotech had revenue of $88.18M in the quarter ending March 31, 2025, with 94.88% growth. This brings the company's revenue in the last twelve months to $333.45M, up 247.53% year-over-year. In the year 2024, Krystal Biotech had annual revenue of $290.52M with 473.02% growth.
Revenue (ttm)
$333.45M
Revenue Growth
+247.53%
P/S Ratio
11.90
Revenue / Employee
$1,212,538
Employees
275
Market Cap
3.99B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
KRYS News
- 4 weeks ago - Krystal Biotech to Present at BofA Securities 2025 Health Care Conference - GlobeNewsWire
- 5 weeks ago - Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 6 weeks ago - Krystal Biotech to Present at Upcoming Scientific Conferences - GlobeNewsWire
- 2 months ago - Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer - GlobeNewsWire
- 2 months ago - Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK - Seeking Alpha
- 3 months ago - Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 3 months ago - Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus - Seeking Alpha